ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase)
| Written | 2001-08 | Jean-Loup Huret |
| Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France |
(Note : for Links provided by Atlas : click)
1. Identity
| Alias_symbol (synonym) | General Information |
| AICARFT | |
| IMPCHASE | |
| Other alias | AICARFT/IMPCHASE (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase) |
| HGNC (Hugo) | ATIC |
| LocusID (NCBI) | 471 |
| Atlas_Id | 227 |
| Location | 2q35 [Link to chromosome band 2q35] |
| Location_base_pair | Starts at 215311956 and ends at 215349773 bp from pter ( according to hg19-Feb_2009) [Mapping ATIC.png] |
 | |
| ATIC (2p35) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics. | |
| Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
| ALK (2p23.2) / ATIC (2q35) | ATIC (2q35) / ALK (2p23.2) | ATIC (2q35) / ATIC (2q35) | |
| ATIC (2q35) / NAB1 (2q32.2) | EFNB2 (13q33.3) / ATIC (2q35) | FAM117B (2q33.2) / ATIC (2q35) | |
| PDCD11 (10q24.33) / ATIC (2q35) | SNUPN (15q24.2) / ATIC (2q35) |
2. DNA/RNA
| Transcription | 1776 bp mRNA; transcribed in a centromeric to telomeric orientation |
3. Protein
| Description | 591 amino acids, 64 kDa; two functional domains separated by a linker region with a dimerization domain (amino acids 170 to 199): amino acids 1 to 169 encode the IMP cyclohydrolase (IMPCH) function, and amino acids 200 to 591 encode the 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT) function; homodimer |
| Expression | wide |
| Function | bifunctional purine biosythesis:9th and 10th step of the de novo purine synthesis |
| Homology | belongs to the PURH family |
4. Implicated in
| Note | |
| Entity | inv(2)(p23q35) --> ATIC- ALK |
| Disease | found in rare cases of ALK+ anaplasic large cell lymphoma |
| Cytogenetics | hidden translocation most often |
| Hybrid/Mutated Gene | 5' ATIC - 3' ALK |
| Abnormal Protein | 791 amino acids, 87 kDa. 229 N-term amino acid from ATIC containing the IMPCH domain and the dimerization domain fused to the 562 C-term amino acids from ALK (i.e. the entire cytoplasmic portion of ALK with the tyrosine kinase domain); cytoplasmic localisation only. |
| Oncogenesis | ATIC seems to provoke the dimerization of ATIC-ALK, which should lead to constitutive autophosphorylation and activation of the ALK tyrosine kinase, as for NPM1-ALK (see t(2;5)(p23;q35) ). |
5. Bibliography
| Structure and functional relationships in human pur H. |
| Beardsley GP, Rayl EA, Gunn K, Moroson BA, Seow H, Anderson KS, Vergis J, Fleming K, Worland S, Condon B, Davies J |
| Advances in experimental medicine and biology. 1998 ; 431 : 221-226. |
| PMID 9598063 |
| ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). |
| Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M |
| The American journal of pathology. 2000 ; 156 (3) : 781-789. |
| PMID 10702393 |
| Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. |
| Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG |
| Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2000 ; 14 (9) : 1533-1559. |
| PMID 10994999 |
| Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. |
| Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S, Schlegelberger B, Peeters B, De Wolf-Peeters C, Wlodarska I, Morris SW |
| Blood. 2000 ; 95 (6) : 2144-2149. |
| PMID 10706887 |
| Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. |
| Morris SW, Xue L, Ma Z, Kinney MC |
| British journal of haematology. 2001 ; 113 (2) : 275-295. |
| PMID 11380391 |
| The human purH gene product, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase. Cloning, sequencing, expression, purification, kinetic analysis, and domain mapping. |
| Rayl EA, Moroson BA, Beardsley GP |
| The Journal of biological chemistry. 1996 ; 271 (4) : 2225-2233. |
| PMID 8567683 |
| CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. |
| Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B |
| Blood. 2000 ; 96 (12) : 3681-3695. |
| PMID 11090048 |
| Characterization of molecularly cloned human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase. |
| Sugita T, Aya H, Ueno M, Ishizuka T, Kawashima K |
| Journal of biochemistry. 1997 ; 122 (2) : 309-313. |
| PMID 9378707 |
| A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. |
| Trinei M, Lanfrancone L, Campo E, Pulford K, Mason DY, Pelicci PG, Falini B |
| Cancer research. 2000 ; 60 (4) : 793-798. |
| PMID 10706082 |
6. Citation
| This paper should be referenced as such : |
| Huret, JL |
| ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase) |
| Atlas Genet Cytogenet Oncol Haematol. 2001;5(4):254-255. |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://atlasgeneticsoncology.usal.es/classic/Genes/ATICID227.html |
7. Other Leukemias implicated (Data extracted from papers in the Atlas) [ 2 ]
|
Anaplastic large cell lymphoma (ALCL)
inv(2)(p23q35) ATIC/ALK |
| Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 3 ] |
|
Soft Tissues: Inflammatory myofibroblastic tumor
Soft tissue tumors: an overview t(2;2)(q33;q35) FAM117B/ATIC |
8. External links
| REVIEW articles | automatic search in PubMed |
| Last year publications | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Thu Jan 17 18:49:06 CET 2019 |
For comments and suggestions or contributions, please contact us atlasgeneticsoncology@usal.es.